KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Accounts Payables (2020 - 2025)

Historic Accounts Payables for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $53.1 million.

  • AbCellera Biologics' Accounts Payables fell 121.99% to $53.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.1 million, marking a year-over-year decrease of 121.99%. This contributed to the annual value of $55.0 million for FY2024, which is 1093.99% up from last year.
  • According to the latest figures from Q3 2025, AbCellera Biologics' Accounts Payables is $53.1 million, which was down 121.99% from $50.1 million recorded in Q2 2025.
  • Over the past 5 years, AbCellera Biologics' Accounts Payables peaked at $55.0 million during Q4 2024, and registered a low of $13.3 million during Q1 2021.
  • Moreover, its 5-year median value for Accounts Payables was $42.9 million (2024), whereas its average is $38.5 million.
  • In the last 5 years, AbCellera Biologics' Accounts Payables surged by 11482.16% in 2023 and then tumbled by 1611.41% in 2024.
  • Over the past 5 years, AbCellera Biologics' Accounts Payables (Quarter) stood at $32.0 million in 2021, then skyrocketed by 63.97% to $52.5 million in 2022, then decreased by 5.56% to $49.6 million in 2023, then grew by 10.94% to $55.0 million in 2024, then dropped by 3.43% to $53.1 million in 2025.
  • Its last three reported values are $53.1 million in Q3 2025, $50.1 million for Q2 2025, and $47.8 million during Q1 2025.